All In Biotech

NDA 016608 · Novartis

Tegretol

Carbamazepine · Oral · Mood Stabilizer

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1968

Mar 11, 1968

Approved uses

4

Original approval plus efficacy supplements

Registered trials

199

31 Phase 3, 6 recruiting

FAERS reports

64,113

55,674 serious, 5,490 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNINGS SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH TEGRETOL. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH TEGRETOL. PATIENTS TESTING...

What it is approved for

From the label in effect Aug 20, 2026.

INDICATIONS AND USAGE Epilepsy Tegretol is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of Tegretol as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by Tegretol (see PRECAUTIONS, General). Trigeminal Neuralgia Tegretol is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.

Mechanism: Mechanism of Action Tegretol has demonstrated anticonvulsant properties in rats and mice with electrically and chemically induced seizures. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. Tegretol greatly reduces or abolishes pain induced by stimulation of the infraorbital nerve in cats and rats. It depresses thalamic potential and bulbar and polysynaptic reflexes, including the linguomandibular reflex in cats. Tegretol is chemically unrelated to other anticonvulsants or other drugs used to control the pain of trigeminal neuralgia. The...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 11, 1995 Supplement 59 · Efficacy
  • Jul 31, 1987 Supplement 48 · Efficacy
  • Jun 2, 1986 Supplement 54 · Efficacy
  • Mar 11, 1968 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
  • TEGRETOL · CARBAMAZEPINE 200MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Carbamazepine" as an intervention, any sponsor and status, largest first.

All 199 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,921
  • drug interaction3,445
  • seizure3,415
  • fall2,937
  • dizziness2,757
  • toxicity to various agents2,741
  • off label use2,709
  • pyrexia2,675
  • nausea2,566
  • vomiting2,471
  • fatigue2,354
  • convulsion2,345

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,434
20051,784
20061,707
20071,643
20081,892
20092,340
20102,297
20112,506
20123,243
20132,514
20142,798
20153,402
20163,483
20173,586
20184,321
20194,062
20203,380
20213,724
20223,244
20232,864
20242,857
20252,849
20262,176

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tegretol (Carbamazepine)

2024 spending

$11.6M

Beneficiaries

3,532

21,732 claims

Per beneficiary

$3,279

$2.67 per unit

View as table
YearSpending
2020$13,773,591
2021$13,081,659
2022$12,344,580
2023$13,119,143
2024$11,581,199

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,614 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.